Join
Live feed
·
PRReleasevia Quantisnow
Beam Therapeutics Inc. logo

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

ByQuantisnow·Wall Street's wire, on your screen.
BEAM· Beam Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BEAM (Beam Therapeutics Inc.) and more on Quantisnow.